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Abstract
Heart failure is a major health problem worldwide with a significant morbidity and mortality rate. Although studied exten-
sively in animal models, data from patients at the compensated disease stage are lacking. We sampled myocardium biopsies 
from aortic stenosis patients with compensated hypertrophy and moderate heart failure and used transcriptomics to study the 
transition to failure. Sequencing and comparative analysis of analogous samples of mice with transverse aortic constriction 
identified 25 candidate genes with similar regulation in response to pressure overload, reflecting highly conserved molecular 
processes. The gene cysteine-rich secretory protein LCCL domain containing 1 (CRISPLD1) is upregulated in the transition 
to failure in human and mouse and its function is unknown. Homology to ion channel regulatory toxins suggests a role in 
 Ca2+ cycling. CRISPR/Cas9-mediated loss-of-function leads to dysregulated  Ca2+ handling in human-induced pluripotent 
stem cell-derived cardiomyocytes. The downregulation of prohypertrophic, proapoptotic and  Ca2+-signaling pathways upon 
CRISPLD1-KO and its upregulation in the transition to failure implicates a contribution to adverse remodeling. These 
findings provide new pathophysiological data on  Ca2+ regulation in the transition to failure and novel candidate genes with 
promising potential for therapeutic interventions.
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Introduction
Systolic heart failure (HF) is a leading cause of hospital 
admission and mortality in industrialized nations. Despite 
extensive efforts, progress in the development of new 
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specific drugs is lacking [39]. Hence, there is significant 
interest in developing therapies that block or reverse the del-
eterious effects of prolonged cardiac stress.
The first response of the heart upon a cardiac insult 
(such as hypertension, valvular stenosis or insufficiency) is 
a compensated hypertrophy (CH) with preserved ejection 
fraction (EF) and cardiac function. This adaptive response is 
accompanied by molecular changes that impair contractility 
over time leading to “decompensated” HF with decreased 
cardiac function and left ventricular dilation [16, 26, 47, 
49]. Life-threatening symptoms such as mechanical failure 
and arrhythmias in later stages lead to the poor outcome of 
this complex disease [33]. The terminal “end stage” of HF 
(tHF) has been analyzed using myocardium samples from 
heart transplantation surgeries [3, 44, 48, 53]. However, due 
to the unavailability of patient samples, there is a lack of 
data regarding the molecular transition from health to CH 
and moderate HF (mHF). Primary sources for the analysis 
of progression steps during disease development are ani-
mal models. However, despite a common phenotype, results 
gained from animal models cannot necessarily be transferred 
to the human situation [8, 11, 23]. RNA-sequencing (RNA-
seq) screens in a variety of animal HF models and human 
tHF showed divergence in mRNA expression profiles [1, 2, 
5, 28, 42, 45]. Hence, adequate models for understanding the 
transcriptional basis of HF disease progression are missing.
To identify novel functional target genes in the human 
heart during disease progression in response to pressure 
overload (PO), we carried out an RNA-seq screen in human 
myocardium of aortic stenosis (AS) patients in compari-
son with control myocardium from potential organ donors. 
Aortic valve replacement procedure enabled to collect myo-
cardium samples of patients with AS and CH and normal 
EF and mHF with reduced EF. To compare the human data 
to the mouse model of PO-induced CH and mHF, we con-
ducted RNA-seq at similar stages in the transverse aortic 
constriction (TAC) mouse model. The direct comparison of 
human and mouse gene expression profiles led to the identi-
fication of 25 genes regulated analogously in the human and 
the mouse heart in response to PO.
The candidate gene cysteine-rich secretory protein 
LCCL domain containing 1 (CRISPLD1) is secreted and 
was previously found in the secretome of choroid plexus 
epithelial cells [29] and exosomes of human parotid gland 
[19] and prostatic secretions [40]. There is no literature 
available on either human or mouse CRISPLD1 function. 
However, CRISPLD1 contains allergen V5/Tpx-1-related 
conserved sites, which have been shown to be evolutionar-
ily related to helothermine, a toxin found in the venom of 
the Mexican beaded lizard (Heloderma horridum horridum) 
that blocks cardiac ryanodine receptor (RyR) channels and 
 Ca2+-induced  Ca2+ release (CICR) [32, 34, 35].
Ca2+ plays a central role in the heart and in HF develop-
ment [20, 22, 31]. Remodeling of  Ca2 handling accounts to 
contractile dysfunction and arrhythmogenesis, responsible 
for the detrimental outcome of HF [27]. CRISPLD1 upregu-
lation during the transition to HF and its sequence homology 
to toxins such as helothermine implicated a functional role in 
regulation of  Ca2+ cycling and thus cardiac contraction dur-
ing disease development. Therefore, we investigated the role 
of CRISPLD1 by CRISPR/Cas9-mediated loss-of-function 
experiments in human-induced pluripotent stem cell-derived 
cardiomyocytes (hiPSC-CM). Confocal  Ca2+ imaging of 
hiPSC-CM show an increase in  Ca2+ transient (CaT) ampli-
tude, CaT rise time and a faster CaT decay after CRISPLD1 
knock out (CRISPLD1-KO). Accordingly, this indicates that 
CRISPLD1, a previously uncharacterized secretory protein, 
plays an inhibitory role in  Ca2+ handling in human CM and 
might have a detrimental effect on regulation of  Ca2+cycling 
during disease development. Analysis of the CRISPLD1-KO 
transcriptome and proteome and CRISPLD1 upregulation 
during HF progression suggests a contribution to the fail-
ing phenotype of the heart. Thus, deep RNA-seq in patients 
at the transition to HF identified the novel candidate gene 
CRISPLD1 as a regulator of  Ca2+ cycling.
Results
Transcriptomics in human transition from CH 
to mHF and TAC‑mice
Biopsy samples from human myocardium were obtained 
from aortic valve replacement surgery (see suppl. Table 1 
for clinical characteristics). Figure 1a, b details the samples 
that were used for sequencing. The following groups were 
compared: a non-failing (NF) control group with four left 
ventricular myocardial samples from healthy donor hearts 
and two pathology groups of AS patients, each consisting 
out of five replicates and being matched for age and sex. A 
terminal heart failure group (tHF) with six left ventricular 
myocardial samples from transplanted hearts of patients suf-
fering dilated cardiomyopathy (DCM) was used as out-group 
(see suppl. data file S1 for differential gene expression data). 
The major difference between the two AS pathology groups 
is the ejection fraction (EF), which is preserved with values 
over 55% (58.4% ± 2.9) in the CH group and reduced with 
values of about 33% (33.5% ± 4.1) in the mHF group (graph 
Fig. 1a and suppl. Table 1).
To compare the human data to the mouse model of PO-
induced CH and HF, we conducted RNA-seq at similar 
stages in the TAC mouse model using exactly the same 
methodology as for the human samples (Fig. 1c, see suppl. 
Fig. S1 for mouse echocardiography/morphometry). CH 
was compared to animals 1  week post-treatment (PT) 
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(1wTAC) showing a mean preserved EF of 63% (± 2.7). 
mHF was compared to mice 8 weeks PT (8wTAC). 8wTAC 
animals show a significant reduction in EF (47% ± 2.2) 
comparable to the human situation. With this approach, 
we received for the first time a highly comparative dataset 
which allowed us to set up expression profiles of tran-
scriptomic changes at different stages of PO in human 
AS patients (suppl. data S1) and mice after TAC (suppl. 
methods, suppl. data S2, suppl. Fig. S2). Principle compo-
nent analysis (PCA) of the NF, CH mHF and tHF groups 
showed a low variation within the groups but allow a clear 
distinction due to high variation between NF, CH mHF and 
tHF (suppl. Fig. S3). PCA of biological mouse replicates 
also showed a clear distinction between control (sham) and 
treatment (TAC) groups (suppl. Fig. S4). The expression 
of known marker genes for CH and HF was validated by 
qPCR (suppl. Fig. S5). NPPB increases dramatically in 
expression in mHF compared to the control and MEF2A 
and MYH7 increase significantly in both conditions com-
pared to the control.
We identified 25 genes that are regulated in a conserved 
manner in human and mouse HF progression (Fig. 1e) 
using highly stringent filtering (suppl. methods). Litera-
ture research was conducted to verify CH and HF pathol-
ogy-related functions of the identified candidates using 
the available public databases (suppl. Table 2). Among 
the genes that are progressively upregulated in the transi-
tion to HF is CRISPLD1, a gene of unknown biological 
function (Fig. 1e and suppl. Table 2). Transcriptomics 
in human and mice led to the identification of candidate 
genes with a potential functional role in the transition 
Fig. 1  RNA-seq of PO-induced 
CH and mHF in human and 
mouse myocardium. a EF 
of AS patients with CH and 
mHF. Error bars represent 
mean ± SEM. b Workflow of 
RNA-seq screen of human 
NF samples (n = 4), human 
AS patients with CH (n = 5) 
and mHF (n = 5) and c of 
mice 1 week (CH) (n = 4) and 
8 weeks (mHF) after TAC 
(n = 5). Error bars represent 
mean ± SD. d EF of mice 
1wTAC and 8wTAC. Error 
bars represent mean ± SEM. 
e Expression profiles of con-
served DEGs in human and 
mouse transcriptomes during 
disease progression illustrated 
as heatmap. The light blue to 
dark red shading scale reflects 
the logFC of median normal-
ized counts. Genes expressed 
in the same way in human and 
mouse datasets according to 
disease progression are framed. 
CRISPLD1 is highlighted in 
red. EF ejection fraction, AS 
aortic stenosis, CH compen-
sated hypertrophy, mHF moder-
ate heart failure, NF non-failing 
control, 1wTAC 1 week post-
transverse aortic constriction, 
8wTAC 8 weeks post-transverse 
aortic constriction, DEGs differ-
entially expressed genes, logFC 
log fold change. n = 4–5/group
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process and more specifically the previously uncharacter-
ized CRISPLD1 gene.
CRISPLD1: a novel uncharacterized candidate 
in the transition to HF
Based on the expression profiles during HF progression 
in human and mouse transcriptomes and after extensive 
literature search, we decided to functionally test the role 
of the gene cysteine-rich secretory protein LCCL domain 
containing 1 (CRISPLD1).
CRISPLD1 is expressed at low levels in human and 
mouse NF myocardium, increases significantly in CH (log-
2foldchange = 1.6) and 1wTAC (log2foldchange = 1.5) and 
increases once more in mHF (log2foldchange = 2.6) and 
8wTAC (log2foldchange = 2.3) (Fig. 2a). The sequencing 
results were validated by qPCR (Fig. 2b) and we also find 
CRISPLD1 to be expressed in fetal ventricle in hiPSC-CM 
and human cardiac fibroblasts (Fig. 2c).
The biological function of CRISPLD1 in the heart is to 
our knowledge not described in the existing literature, nei-
ther in human nor in mouse. Intriguingly, this secretory pro-
tein belongs to the highly conserved CRISP/Antigen 5/PR-1 
(CAP) superfamily and contains (beside the CAP domain 
and two LCCL domains) V5/Tpx-1-conserved sites, which 
have been shown to be evolutionarily related to  Ca2+channel 
regulating toxins such as the lizard toxin helothermine 
(Fig. 2d). Alignment of the CRISPLD1 protein sequence 
to the cysteine-rich venom protein helothermine (Fig. 2d) 
shows sequence conservation within the CAP domain and a 
high degree of conservation between the V5/Tpx-1 CRISP 
family signature 1 (position 167–177 of CRISPLD1, 80% 
identity) and signature 2 (position 201–212 of CRISPLD1, 
60% identity).
Fig. 2  Expression profile, qPCR validation and protein structure of 
CRISPLD1. a Expression profile of CRISPLD1 in NF, CH and mHF 
determined by RNA-seq. Given are the reads (rpm) of AS patients 
and mice (sham = NF, 1wTAC = CH and 8wTAC = mHF); asterisks 
represent FDR-corrected p values. b qPCR validation of CRISPLD1 
expression profiles in human and mouse NF (= human non-failing 
myocardium or mice sham non-failing myocardium), CH and mHF 
myocardium. c Expression of CRISPLD1 determined by RNA-seq 
(given as rpkm) in human fetal ventricle, adult ventricle, hiPSC-CM 
and cardiac fibroblasts (CF). d Protein structure of CRISPLD1 show-
ing the CAP domain (155 aa, highlighted in blue) and two V5/Tpx-1 
conserved sites (10aa and 12 aa, respectively, highlighted in orange. 
The two LCCL domains at the C-terminus are highlighted in black. 
The alignment shows conservation of CRISPLD1 and the cysteine-
rich venom protein helothermine (CRVP_HELHO) protein sequence 
within the CAP domain (underlined in blue) and the two V5/Tpx-1 
sites (orange letters, CRISPLD1 position 167–177 CRISP fam-
ily signature 1; CRISPLD1 position 201–212 CRISP family signa-
ture 2). Alignment was generated using blastp. Error bars represent 
mean ± SEM. rel. relative, a.u. arbitrary units, EF ejection fraction, 
NF non-failing control, AS aortic stenosis, CH compensated hyper-
trophy, mHF moderate heart failure, NF non-failing control, hiPSC-
CM human-induced pluripotent stem cell-derived cardiomyocytes. 
n = 4–5/group
Basic Research in Cardiology          (2020) 115:27  
1 3
Page 5 of 16    27 
Therefore, we decided to study the function of CRISPLD1 
in a human CM model system with respect to the hypotheti-
cal  Ca2+ regulating function. To get insights into CRISPLD1 
function in human iPSC-CM, we introduced a genomic dele-
tion in hiPSC via CRISPR/Cas9. Genome editing generated 
a 34 bp deletion located in exon 7, affecting all the three 
CRISPLD1 isoforms (Fig. 3a). Due to exon skipping as a 
consequence of the deletion, 303 bp of the mRNA are lost 
during transcription, resulting in an in-frame deletion of 101 
amino acids (aa), affecting the major functional domains 
of the protein including the V5/Tpx-1 sites (Fig. 3b, c and 
suppl. information S8 for sequence information).
Next, we validated the deletion on mRNA level in 
hiPSC-CM via qPCR. No expression was detectable using 
a primer pair that was designed to amplify the deleted 
region (Fig. 3d). qPCR and sequencing of amplicons with 
primer pairs spanning regions outside the deletion showed, 
that there is still CRISPLD1 mRNA detectable. However, 
this mRNA lacks sequence information within the CAP, 
V5/Tpx-1 and LCCL domains and is significantly down 
regulated in all the three isoforms compared to the control 
(Fig. 3e and suppl. information S8). Therefore, we assume 
a functional KO of the CRISPLD1 protein.
CRISPR/Cas9-mediated functional KO of CRISPLD1 in 
hiPSC allowed us to test the role of CRISPLD1 in calcium 
cycling (as indicated by its sequence similarity to previously 
described calcium regulators) in human cardiomyocytes.
CRISPLD1‑KO affects calcium cycling in hiPSC‑CM
Next, we conducted cellular and functional analysis of CaT 
and by confocal calcium imaging. The CRISPLD1-KO and 
the corresponding isogenic WT hiPSC line were differenti-
ated into mainly ventricular-like functional CM. WT- and 
CRISPLD1-KO-hiPSC-CM were cultured up to 60 days for 
adequate maturation.
CRISPLD1-KO showed no obvious effects on differ-
entiation efficiency and contractile function compared to 
Fig. 3  Structure of CRIPLD1-
KO. a A 34 bp genomic DNA 
(gDNA) deletion located in 
exon 7 was introduced via 
CRISPR/CAS9. b Exon skip-
ping leads to a loss of 303 
base pairs (bp; exon 6–8) at 
mRNA level, causing a dele-
tion c of 101 aa (amino acids, 
highlighted in red), affecting 
the functional domains of the 
protein. d qPCR of the deleted 
region on mRNA level in 
CRISPLD1-KO-CM and WT 
controls. e qPCR showing a 
significant reduction of the 
mRNA of all isoforms. Primer 
locations are indicated as arrows 
in (b). Error bars represent 
mean ± SEM. WT-CM wild-type 
control hiPSC-CM, KO-CM 
CRISPLD1-KO-hiPSC-cardi-
omyocytes, rel. relative, a.u. 
arbitrary units; each data point 
reflects a mean of 3 technical 
qPCR replicates of n = 3 inde-
pendent differentiations/group
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WT-hiPSC-CM. Immunofluorescence analysis of KO-
hiPSC-CM compared to WT-hiPSC-CM (Fig. 4a) showed 
normal cardiac marker expression. Cardiac contraction 
filaments were stained with anti-α-actinin (ACTN) and 
cardiac troponin (cTNT). The ventricular isoform of the 
myosin light chain 2 (MLC2V) antibody was used to 
Fig. 4  Characterization and functional analysis of CRISPLD1-KO-
hiPSC-CM. a Representative images of immunofluorescence stain-
ings of CM markers with anti-Myosin Light Chain 2 (MLC2V; 
green), anti-sarcomeric α-Actinin (ACTN; red), anti-cardiac Tro-
ponin T (cTNT; red), anti-Connexin 43 (CX43; green) and Anti-
cardiac muscle ryanodine receptor (RyR2; green). Nuclei are shown 
in blue and stained with Hoechst33342. b–i Functional analysis of 
CRISPLD1-KO-hiPSC-CM at day 60–80 by confocal calcium imag-
ing. b  Ca2+ transient (CaT) amplitude c CaT rise time and d CaT 
decay at 50% of WT-hiPSC-CM, CRISPLD1-KO-hiPSC-CM and 
WT-hiPSC-CM treated with helothermine. e  Ca2+ transient (CaT) 
amplitude f CaT rise time and g CaT decay at 50% of WT-hiPSC-
CM, CRISPLD1-KO-hiPSC-CM and CRISPLD1-KO-hiPSC-CM 
treated with helothermine. h Overlay of representative single cell 
recordings of CaT of WT CM (blue), CRISPLD1-KO CM (red) and 
WT CM treated with helothermine (orange). i Overlay of representa-
tive single cell recordings of CaT of WT (blue) and CRISPLD1-
KO CM treated with helothermine (purple). Error bars represent 
mean ± SD. hiPSC-CM human-induced pluripotent stem cell-derived 
cardiomyocytes, WT wild-type control, KO knock out, WT HELHO 
wild-type control treated with helothermine, KO HELHO knock out 
treated with helothermine, HELHO helothermine, s second. n = 181 
cells (WT); n = 183 cells (KO)
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determine the ventricular identity of CM. The expression 
of ACTN and cTNT displayed regular organization of car-
diac sarcomeres. There were no noticeable alterations in 
the expression patterns of MLC2V, cTNT and the cardiac-
specific gap junction protein CX43. Furthermore, RyR2 
was detectable in a CM-specific expression pattern in both 
WT-hiPSC-CM and KO-hiPSC-CM.
As we hypothesize a functional role of CRISPLD1 in 
calcium cycling, we carried out CaT analysis by confo-
cal calcium imaging of CRISPLD1-KO-CM compared 
to WT-control-CM (Fig. 4b—i). Compared to WT con-
trols, CRISPLD1-KO-CM show a significant increase 
in CaT amplitude (WT mean = 2.8, KO mean = 3.5; 
Fig. 4b, e), a significant increase in CaT rise time (WT 
mean = 169.5 ms, KO mean = 199.0 ms; Fig. 4c, f) and a 
significant decrease in CaT decay (WT mean = 603.5 ms, 
KO mean = 460.8 ms; Fig. 4d, g), pointing towards higher 
systolic CaT in KO-CM.
To further validate the calcium-imaging data and to 
test the effect of CRISPLD1-KO upon toxin treatment 
with a known  Ca2+ regulator, we treated WT-control-CM 
and CRISPLD1-KO-CM with helothermine. WT-con-
trol-CM exhibit a significantly decreased CaT amplitude 
upon helothermine treatment compared to WT controls 
without treatment (WT mean = 2.8, KO mean = 3.5, WT 
HELHO mean = 2.5; Fig. 4b, h). The CaT rise time is sig-
nificantly increased in WT-CM treated with helothermine 
compared to WT-controls (WT mean = 169.5  ms, KO 
mean = 199.0 ms, WT HELHO = 207.1 ms; Fig. 4c, h). 
The CaT decay is significantly increased upon helother-
mine treatment compared to WT controls without treat-
ment (WT mean = 603.5 ms, KO mean = 460.8 ms, WT 
HELHO mean = 731. 9 ms; Fig. 4d, h). CRISPLD1-KO-
CM do not show a significant alteration in CaT amplitude 
after helothermine treatment compared to WT-control-
CM. Instead, the CaT amplitude is of normal WT range 
(WT mean = 2.9, KO mean = 3.5, KO HELHO mean = 2.8; 
Fig. 4e, i). This is also true for the CaT rise time: the 
significant increase observed in WT helothermine-treated 
CM is not detectable in CRISPLD1-KO-CM treated with 
helothermine and is rather comparable to WT controls 
(WT mean = 169.5 ms, KO mean = 199.0 ms, KO HELHO 
mean = 170.0 ms; Fig. 4f, i). The increased CaT decay 
in WT helothermine-treated CM is still detectable in 
the CRISPLD1-KO-CM line treated with helothermine, 
but to a much lower degree (WT mean = 603.5 ms, KO 
mean = 460.8 ms, KO HELHO mean = 650.2 ms; Fig. 4g, 
i).
We were able to detect a functional, measurable effect 
on CaT in CRISPLD1-KO-CMs (increased  Ca2+ amplitude 
and  Ca2+rise time and decreased  Ca2+decay). CRISPLD1-
KO is able to rescue the CaT phenotype produced by 
treatment with the  Ca2+ regulating toxin helothermine 
(normalization of  Ca2+ amplitude and  Ca2+rise time). This 
loss-of-function and rescue experiments support the con-
verse argument, that CRISPLD1 plays an inhibitory role 
in CM  Ca2+ cycling.
Transcriptomics reveal downregulation of WNT‑, 
apoptosis‑, TGF‑beta and calcium signaling 
in response to CRISPLD1‑KO
To get deeper insights into the biological function of 
CRISPLD1 in hiPSC-CM, samples from four independent 
differentiation experiments of WT control and CRISPLD1-
KO-hiPSC-CM at day 60 (using three replicates for each 
differentiation) were sequenced for transcriptomics. PCA 
showed a clear distinction between control and KO repli-
cates (suppl. Fig. 6) and differential expression analysis led 
to 3583 significantly regulated genes (suppl. data S3 and 
Fig. 5). 73% of the DEGs are downregulated in response 
to CRISPLD1-KO and 27% are upregulated (Fig. 5). Func-
tional pathway and network analysis identified a highly inter-
connected functional network of GO/pathway terms, repre-
senting 85% of downregulated DEGs (Fig. 5 and suppl. data 
S4). Among the most significant downregulated pathways 
are apoptosis signaling, TGF-beta signaling pathway, TNF 
signaling pathway and transcriptional signaling by TP53 and 
signaling in response to WNT. Interestingly, genes associ-
ated to potassium ion transmembrane transporter activity, 
arrhythmogenic right ventricular cardiomyopathy, calcium 
signaling pathway, ion homeostasis and muscle contraction 
are functionally grouping, as well as genes associated to 
adenylate cyclase pathway, G alpha (s) signaling, PLC beta 
and G alpha (q) signaling. 76% of the upregulated genes are 
associated to pathway terms such as voltage-gated sodium 
channel activity, ion transmembrane transporter activity and 
inorganic cation transmembrane transporter activity (suppl. 
data S5).
As these pathways relate to the functional changes, which 
we observed by CaT analysis in CRISPLD1-KO-CM, we 
visualized the changes in gene expression in CM adrener-
gic signaling using KEGG search and color pathway (sum-
marized in Fig. 5b, for detailed analysis, see suppl. Fig. 
S7a and suppl data S6). Representative gene expression 
changes observed by RNA-seq were validated by qPCR 
(suppl. Fig. S7b). The detailed analysis of the adrenergic 
signaling pathway in human CM shows a significant down-
regulation of ADRB1 mRNA (encoding adrenoceptor beta 
1). Transcripts of ßAR-signaling downstream targets (genes 
encoding AC, Epac, p38MAPK, Gi, PI3K, AKT, CREB) 
and angiotensin II receptor type 1 (AGTR1) are downregu-
lated as well. Among upregulated genes are ADRA1B, the 
RYR2 gene as well as genes encoding the cardiac sodium 
channel (SCN5A, SCN4B), while genes encoding the potas-
sium channel (KCNE1), the catalytic subunit alpha-2 of the 
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sodium–potassium ATPase (ATP1A2) and the l-type cal-
cium channel (LTCC, CACNA2D2) are downregulated. To 
validate these findings, we carried out proteomics of WT 
control and CRISPLD1-KO-hiPSC-CM at day 60. Analysis 
of the liquid chromatography–tandem mass chromatography 
(LC–MS/MS) data revealed an upregulation of the cardiac 
ryanodine receptor (RYR2) and the cardiac sodium channel 
(SCN5A) on protein level as well as downregulation of the 
LTCC CACNAD3 protein and the ATPase Na + /K + trans-
porting subunit alpha 3 (ATP1A3) (Fig. 5b and suppl data 
S7).
Thus, transcriptomics of human WT-CM and CRISPLD1-
KO-CM led to the identification of regulated pathways spe-
cifically enriched upon CRISPLD1 loss-of-function. These 
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pathways relate to the functional changes observed in the 
CaT analysis and deeper analysis of the adrenergic signaling 
pathway and proteome analysis support the functional role 
of CRISPLD1 in calcium cycling in human CM.
Discussion
With a set of human myocardium biopsy samples of AS 
patients at two stages of HF progression, namely CH and 
mHF and healthy donor LV myocardium, we were able to 
conduct expression profiling in the human heart in response 
to PO. Analogous myocardium samples were obtained from 
TAC mice. We identified 25 genes with well-conserved 
expression profiles during HF progression in human and 
mouse. Among the candidates was a previously uncharacter-
ized gene, CRISPLD1. We identified a novel functional role 
of CRISPLD1 in the regulation of  Ca2+ handling in human 
CM and the transition to failure.
Using two time points, 1 week and 8 weeks post-TAC, we 
aimed to compare the human data to the TAC mouse model 
of PO-induced CH and HF. RNA-seq and the direct com-
parison of human and mouse gene expression profiles led to 
the identification of a set of 25 genes with analogous regula-
tion in the human and the mouse heart in response to PO.
The direct stringent comparison of human and mouse 
transcriptomes shows a relative small overlap of molecular 
changes. This is, however, not surprising. Since different 
model systems and etiologies show divergent changes in the 
transcription profiles in response to HF [1, 2, 21, 28, 42]. 
The TAC surgery produces an acute PO as a result of aortic 
banding. On the contrary, human AS patients acquire valvu-
lar stenosis over a time span of years. The dataset presented 
here provides 25 conserved DEGs that are ideal candidates 
for further functional analysis. However, a limitation of this 
study is the number of myocardial AS samples available (five 
CH and five moderate HF), and corresponding four controls, 
which to some extent, limits the more exhaustive identifica-
tion of a larger panel of potential differently expressed genes. 
Yet, the availability of human myocardial samples in general 
but specifically of non-failing control myocardium, patients 
with compensated hypertrophy and sustained cardiac func-
tion and moderate HF are scarce. Therefore, we focused our 
analysis on candidate genes with conserved regulation in the 
mouse model during the transition to heart failure. These 
genes reflect highly conserved molecular processes among 
species independent of the underlying etiology, which give 
rise to the PO-induced phenotype. Furthermore, the dataset 
enables comparative functional experiments in human and 
mouse model systems.
The candidate gene CRISPLD1 is encoding a protein 
that is functionally not described in the heart. It was pre-
viously found in the secretome of choroid plexus epithelial 
cells [29] and exosomes of human parotid gland [19] and 
prostatic secretions [40]. CRISPLD1 was described to be 
expressed in lung fibroblasts and was discussed as a novel 
biomarker for experimental pulmonary fibrosis [4]. It plays 
a role in face morphogenesis and the folic acid pathway [10, 
51] and in chondrocyte response to IL-1α related to cellular 
stress [52]. CRISPLD1 was identified among regulators of 
murine hematopoietic stem cell repopulation [24]. It was also 
found to be regulated in a whole exome sequencing screen for 
cancer gene alterations by mTOR-activated tuberous sclerosis 
complex-associated renal cell carcinoma [38]. Only recently, 
it has been shown that CRISPLD1 polymorphisms alter anti-
platelet potency of clopidogrel in coronary artery disease 
patients in Chinese Han [50] and that CRISPLD1 is differ-
entially methylated during male infertility [46]. We focused 
our analysis on this gene, because it shows a very interesting 
protein structure. CRISPLD1 belongs to the highly conserved 
family of CRISP/Antigen 5/PR-1 (CAP) proteins. CAP 
superfamily proteins are most often secreted and the overall 
structural conservation was proposed to result in fundamen-
tally similar functions for the CAP domain in all members 
[reviewed in [18]]. CAP proteins were shown to play a role in 
a number of diseases including HF. Of note, the CAP member 
peptidase inhibitor 16 (PI16) has been identified as a secreted 
protein involved in the negative regulation of CM size [17]. 
Loss of function of PI16 in CM led to increased cell size 
reorganized sarcomeres. Furthermore, PI16 was suggested to 
may have a role in matrix remodeling in HF. Uniquely among 
the CAP superfamily, the CRISPs have ion channel regula-
tory activity. This was first characterized in helothermine, a 
CRISP from the venom of the poisonous lizard Heloderma 
Fig. 5  Transcriptomics and pathway analysis of CRISPLD1-KO-
hiPSC-CM. a RNA-seq of CRISPLD1-KO-CM resulted in the iden-
tification of 3583 differentially expressed genes (DEGs) compared to 
WT-hiPSC-CM at day 60  (log2 Fold Change > 0.5/< − 0.5, adjusted 
p value < 0.05). 73% of the DEGs are downregulated and 27% are 
upregulated. Analysis of functionally organized gene ontology (GO)/
pathway term network of down—(red square) and upregulated (blue 
square) significantly associated DEGs. The network represents GO/
functional terms as nodes, which are linked based on a predefined 
kappa score level. The size of the nodes reflects the enrichment sig-
nificance of the terms. Functional groups are colored and overlaid 
with the network. Functional groups are represented by their most 
significant (leading) term shown next to the corresponding group. b 
Simplified adrenergic signaling pathway in cardiomyocytes (path-
way map adapted from KEGG entry hsa04261). Significantly regu-
lated components are highlighted (transcriptome: upregulated = blue, 
downregulated = red; proteome: upregulated = green arrow, downreg-
ulated = orange arrow). LTCC = L-type calcium channel Iks = potas-
sium voltage-gated channel INaK = Na + /K + -ATPase; AC  ade-
nylate cyclase, Epac  Rap guanine nucleotide exchange factor, 
p38MAPK  mitogen-activated protein kinase 11, Gi  G protein subunit 
alpha i2, PI3K phosphoinositide-3-kinase, AKT  AKT serine/threo-
nine kinase, Ina  cardiac sodium channel, RyR2  cardiac ryanodine 
receptor, ß1AR  adrenoreceptor beta 1, AT-IIR  angiotensin II receptor 
type 1, α-AR  adrenoceptor alpha
◂
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horridum horridum (Mexican beaded lizard) [32, 34, 35]. 
As CRISPLD1 shows high-sequence homology and has two 
V5/Tpx-1 sites related to CRISP1 and CRISP2 signatures 
(PROSITE patterns PS01009 and PS01010; see also Inter-
Pro database entry B7Z8V9 for CRISPLD1 domain archi-
tecture), we decided to study the function of CRISPLD1 in 
hiPSC-CM. We successfully generated a KO line in hiPSC 
via CRISPR/ CAS9, leading to the loss of parts of the CAP 
domain and V5/TPX-1-related site and to a significant down-
regulation of the remaining mRNA. Next, we examined the 
effect of CRISPLD1 loss-of-function on CM  Ca2+ cycling. 
Quantifying CaT after CRISPLD1-KO compared to WT-CM 
showed a CM-specific function of CRISPLD1 in the regula-
tion of  Ca2+ cycling. CRISPLD1-KO-CM show a significant 
increase in CaT amplitude and rise time and a significant 
decrease in  Ca2+ decay, pointing towards an increase in sys-
tolic CaT as a consequence of CRISPLD1 loss-of-function. 
In order to further strengthen our hypothesis and the data 
gained from CaT experiments, we carried out additional 
functional experiments to test, whether CRISPLD1-KO has 
the ability to rescue the effect of a known calcium regulator. 
We selected the lizard toxin helothermine as the ability of the 
secreted venom protein to block calcium cycling in many cell 
types is well described [32, 34, 35]. Helothermine treatment 
resulted in disturbed calcium transients in WT iPSC-CM 
with significantly decreased CaT amplitude and significantly 
increased CaT rise time and CaT decay. Indeed, CRISPLD1-
KO is able to rescue the CaT phenotype produced by treat-
ment with the  Ca2+ regulating toxin helothermine (normali-
zation of  Ca2+ amplitude and  Ca2+ rise time).
Eventually, we were able to detect a functional, meas-
urable effect on CaT in CRISPLD1-KO-CMs (increased 
 Ca2+ amplitude,  Ca2+ rise time and  Ca2+ decay). As the 
downregulation of CRISPLD1 mRNA leads to an increase 
in CaT, loss-of-function and rescue experiments support 
the converse argument, that CRISPLD1 plays a functional 
inhibitory role in human CM  Ca2+ cycling. The progressive 
increase in CRISPLD1 expression during disease progres-
sion in AS patients points towards a functional role in the 
transition to HF, presumably as a negative regulator of  Ca2+ 
cycling. However, the detailed underlying molecular mecha-
nisms remain to be investigated in the future.
RNA-seq of CRISPLD1-KO-hiPSC-CM compared to 
WT-hiPSC-CM revealed a fundamental role of CRISPLD1 
in human CM homeostasis. The downregulation of prohy-
pertrophic and proapoptotic (G-protein signaling, CREB 
signaling, WNT signaling, TGF-beta signaling, TNF sign-
aling, TP53 signaling) pathways (reviewed in [30]) points 
towards a beneficial downstream effect of CRISPLD1 loss-
of-function on the human CM phenotype. The detailed 
analysis of the adrenergic signaling pathway in human CM 
supports this suggestion. Of note, the gene ADRB1, encod-
ing the adrenoceptor beta 1, is significantly downregulated. 
ADRB1 is the predominant cardiac subtype expressed and 
known to confer increases in inotropy and chronotropy upon 
stimulation [9]. HF is associated to maladaptive chronic 
stimulation of adrenergic signaling, leading to detrimental 
effects on cardiomyocyte growth and function [7, 37]. One 
of the most common therapeutic approach in HF treatment 
using “beta-blockers” is targeting ADRB1 [43]. Further-
more, downstream targets of ßAR-signaling are downreg-
ulated (genes encoding AC, Epac, p38MAPK, Gi, PI3K, 
AKT, CREB). Another frequently used therapeutic strategy 
is the use of angiotensin-converting enzyme (ACE) inhibi-
tors. Angiotensin II receptor type 1 (AGTR1) is significantly 
downregulated in the transcriptome of CRISPLD1-KO-CM. 
Previously, it has been shown that carriers with the mutation 
AGTR1 1166C experience a greater long-term compensa-
tory renin–angiotensin–aldosterone system activation fol-
lowing treatment with candesartan  [13, 14]. Interestingly, 
the alpha1-adrenergic receptor (ADRA1B) previously 
shown to prevent a maladaptive cardiac response to PO [36] 
is upregulated after CRISPLD1 loss-of-function.
Intriguingly, we also observe significant changes 
in expression of genes and proteins encoding major 
 Ca2+-handling proteins. Of note, the cardiac ryanodine 
receptor (RYR2) gene and protein is upregulated in KO-CM, 
as well as the cardiac sodium channel (SCN5A, SCN4B) 
while genes encoding the potassium channel (KCNE1) 
and the catalytic subunit alpha-2 of the sodium–potassium 
ATPase (ATP1A2) are downregulated. These changes on 
transcriptional and protein level could have the potential to 
give rise to functional changes influencing the  Ca2+ homeo-
stasis observed by CaT analysis of CRISPLD1-KO-CM. 
However, these assumptions need to be validated on func-
tional level (e.g. by measuring action potential duration, SR 
 Ca2+load, intracellular  Ca2+/Na+ and  K+ concentrations and/
or—currents) in future studies.
We propose that the significant increase in CaT ampli-
tude and the fast  Ca2+ decay after CRISPLD1-KO might 
lead to a beneficial effect in human iPSC-CM in response 
to stress as a result of  Ca2+ cycling blockade. Our data 
gained from toxin treatment and rescue experiments in 
WT-hiPSC-CM and CRISPLD-KO-hiPSC-CM sup-
port this hypothesis, as disturbed CaT after treatment 
with the  Ca2+ blocking toxin helothermine were res-
cued in CRISPLD1-KO-hiPSC-CM. A beneficial effect 
of CRISPLD1 loss-of-function in hiPSC-CM is further 
supported by transcriptomics, proteomics and pathways 
analysis of CRISPLD1-KO- vs. WT-CM. However, the 
detailed molecular mechanism of CRISPD1-KO affecting 
 Ca2+ cycling and the downstream effect on CM contractile 
performance need to be validated in future studies. None-
theless, the progressive increase in CRISPLD1 expression 
during disease progression in AS patients points towards 
a functional role in the transition to HF, presumably as 
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a negative regulator of  Ca2+ cycling and thus, with the 
potential to augment CaT in the transition to HF to ame-
liorate cardiac contractility.
Materials and methods
Sampling of human myocardium
Human ventricular myocardium was obtained from biopsies 
of patients undergoing aortal valve implantation with mor-
row resection CH (n = 5, EF = 55% [58.4 ± 2.9%]) and mHF 
(n = 5, EF = 33% [33.5 ± 4.1%]). Detailed clinical parameters 
of patients are listed in suppl. Table 1. Freshly explanted 
donor hearts served as healthy control myocardium (NF, 
n = 4) and left ventricular myocardium of explanted hearts 
of four end-stage heart failure patients undergoing cardiac 
transplantation surgery as a result of ischemic or dilated car-
diomyopathy were used for the analysis of the tHF stage. 
Directly after collection, myocardium samples were snap 
frozen in liquid nitrogen and stored at − 80 °C. The investi-
gation conforms with the principles outlined in the Declara-
tion of Helsinki. The study was approved by the institutional 
ethics committee, and all patients provided written informed 
consent for the use of cardiac tissue samples.
Sampling of mouse myocardium
The investigation conforms to the Guide for the Care and 
Use of Laboratory Animals (NIH publication No. 85–23, 
revised 1996) and was performed in accordance with the eth-
ical standards laid down in the Declaration of Helsinki 1964. 
Transverse aortic constriction (TAC) surgery was done using 
a minimally invasive approach as described previously [25]. 
Briefly, 8-week-old female FVBN mice were anesthetized 
using intraperitoneal injections of a mixture of xylazine and 
ketamine. A 27 gauge needle was tied against the aorta using 
a 5-0 non-absorbable suture. After aortic constriction, skin 
was closed and the mice were kept on a heating plate until 
recovering from anesthesia. Sham animals underwent the 
same procedure except banding of the transverse aorta. Mice 
were anesthetized with isoflurane and sacrificed by cervical 
dislocation. The body weight was determined before dissec-
tion. The heart was excised at the aorta and transferred into 
a petri dish filled with sterile saline. A 21 gauge blunt nee-
dle was used for retrograde perfusion with sterile saline to 
remove residual blood. The heart was weighted, atria and the 
right ventricle removed, and the left ventricle weighted again 
before it was snap frozen in liquid nitrogen. Mice echocardi-
ography and morphometry data are shown in suppl. Fig. S1.
Echocardiography
The mice were anesthetized using 1.5% isoflurane, and echo-
cardiography was performed using a VS-VEVO 660/230 
(Visualsonics, Toronto, Canada). 2D-guided M-mode 
images were recorded in the long-axis view at the left mid-
ventricular level. The examiner was blinded towards group 
assignment.
Direct differentiation of hiPSC into hiPSC‑CM
Human iPSC were cultured in feeder-free culture condi-
tions with StemFlex Medium (Thermo Fisher Scientific) on 
Matrigel (BD Bioscience)-coated plates. The experiments 
were performed with the hiPSC line ipWT1.3 (UMGi014-
B.3) from a healthy donor, generated from dermal fibroblasts 
in feeder-free culture conditions using the integration-free 
episomal 4-in-1 CoMiP reprogramming plasmid (Addgene, 
catalog 63726) as described previously [12, 15]. Directed 
differentiation of hiPSC into mainly ventricular-like CM 
was performed by modulation of WNT signaling, as previ-
ously described [12, 15]. In brief, hiPSC with a confluence 
of 80–90% were treated with Cardio Differentiation Medium 
(RPMI 1640 with Glutamax and HEPES (Thermo Fisher 
Scientific), 0.5 mg human recombinant albumin (Sigma-
Aldrich) and 0.2 mg/ml l-ascorbic acid 2-phosphate (Sigma-
Aldrich) supplemented with 4 µM or 6 µM CHIR99021 
(Merck Millipore) for 48 h. Subsequently, CHIR99021 was 
exchanged to 5 µM IWP2 (Merck Millipore) for further 48 h. 
First beating areas were observed around day 8 and medium 
was changed to Cardio Culture Medium (RPMI 1640 with 
Glutamax and HEPES + 2% B27 (Thermo Fisher Scientific), 
respectively. Metabolic selection was performed with Cardio 
Selection Medium (RPMI 1640 without glucose and with-
out HEPES (Thermo Fisher Scientific), 0.5 mg/ml human 
recombinant albumin, 0.2 mg/ml l-ascorbic acid 2-phos-
phate, 4 mM lactate (Sigma-Aldrich) and 4 mM HEPES 
(Sigma-Aldrich) for 5 days. To achieve lower cell densities, 
differentiated cultures were digested on day 20 with 0.25% 
Trypsin/EDTA (Thermo Fisher Scientific). Afterwards, 
cardiomyocytes were cultured for another 7 days with Car-
dio Selection Medium before changing to Cardio Culture 
Medium for further maturation until day 60. Differentiation 
efficiency was examined by observation of contracting areas 
and flow cytometry. In this study, only differentiated cultures 
with > 90% contracting areas were used.
Generation of KO‑hiPSC clones by CRISPR/Cas9
Transfection of the wild-type hiPSC line ipWT1.3 with 
the all-in-one Cas9 and guide RNA (gRNA) expression 
plasmid (Sigma-Aldrich) targeting CRISPLD1 exon 7 was 
performed with the Human Stem Cell Nucleofector Kit 2 
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(Lonza: VPH-5022) and the Amaxa Nucleofector II Device 
(Lonza) according to manufacturer’s instructions. In brief, 
hiPSC with 80–90% confluency were pretreated with 2 µM 
TZV 1 h before transfection. For nucleofection, 2 × 106 
cells were resuspended in DNA–nucleofector mix with 
2 µg CRISPR/Cas9 plasmid and nucleofected using pro-
gram B-016. Subsequently, cells were replated in one well 
of a six-well plate containing StemFlex Medium (Thermo 
Fisher Scientific), 2 µM TZV and 1 × Pen/Strep. 24 h after 
transfection, plasmid- and GFP reporter-positive hiPSC 
were sorted by fluorescence activated cell sorting (FACS). 
Positive transfected cells were seeded at 1 cell per well on a 
96-well plate containing MEF-conditioned MACS medium 
(Miltenyi Biotech), 1 × Pen/Strep, 2 µM TZV and 50 ng/
µl bFGF. First colonies were visible after 10–18 days and 
medium was changed to MACS medium. HiPSC clones were 
expanded and analyzed at genomic level via sequencing. 
The QIAamp DNA Mini kit (Qiagen) was used for genomic 
DNA isolation. DNA products for sequencing were purified 
after agarose gel electrophoresis using the QIAquick Gel 
extraction kit (Qiagen). The PCR products were validated 
by sequencing (SeqLab, Goettingen). Successfully edited 
clones were sequenced at mRNA level for verification of 
posttranscriptional changes induced by nucleotide deletion 
using the SV Total RNA Isolation System (Promega) and 
RT2 First strand kit (Qiagen) for cDNA synthesis.
Confocal calcium imaging
Three independent differentiation experiments of the 
CRISPLD1-KO and the corresponding isogenic WT hiPSC 
line ipWT1.3 were used for cytosolic calcium recordings. 
Cells were replated on matrigel-coated glass cover slips 
(three replicates/differentiation) in lower densities following 
7 days of recovery. For recordings, hiPSC-CM at day 60–80 
were incubated with 5 µM Rhod-2 AM fluorescent cal-
cium indicator (Thermo Fisher Scientific) and 0.02% (w/v) 
Pluoronic F-127 (Thermo Fisher Scientific) in Tyrode`s 
solution (140 mM NaCl, 5.4 mM KCl, 1.8 mM  CaCl2, 1 mM 
 MgCl2, 10 mM HEPES, and 10 mM glucose (pH 7.4) for 
30 min at RT. Recordings were obtained from paced cells in 
Tyrode’s solution only or in Tyrode’s solution supplemented 
with 5 µM helothermine at RT which were field stimulated 
at 0.25 Hz (18 V, 3 ms duration; MyoPacer ES, IonOptix) 
using a recording chamber with platinum electrodes. For 
acquisition, the LSM 710 confocal microscopy system 
(Carl Zeiss) with a 63 × /1.4 NA oil objective and Zen 2009 
software was used and images were captured in line-scan 
mode (512 pixels, 45 μm, 1057.7 Hz, 20,000 cycles, pinhole 
6 AU). Rhod-2 AM was excited at 561 nm and emission 
was detected at 566–646 nm. Post-acquisition analyses of 
changes in intracellular calcium were performed by plotting 
of mean signal intensity as a function of time using ImageJ 
(NIH), polynomial smoothing (6th order, 10 neighbors) of 
raw data using Excel, and final analysis of calcium transients 
using the Peak Analysis Tool in LabChart Pro 8 (ADInstru-
ments) with the following settings: automatic recognition 
of resting membrane potential, TStart 15% of height away 
from resting membrane potential, TRise and TFall is defined 
between 0 and 100% of the peak height. Calcium transient 
(CaT) decay 50 was defined as the time from the maximum 
of the transient until 50% signal decay. CaT rise time was 
defined as the time from start to the maximum of the tran-
sient. For each analyzed cell, the individual data set repre-
sents a mean of 4 CaT recordings. In total, 181 WT cells and 
183 KO cells were measured. Datasets were analyzed using 
Excel and R. Statistics were performed using two-tailed stu-
dent’s t-test and one-way ANOVA with random effects. Data 
are presented as mean ± SD.
Immunocytochemical staining
Human iPSC-CM were replated in lower density on 
matrigel-coated glass cover slips. After 7 days of recovery, 
cells were fixated with 4% PFA for 20 min at RT and subse-
quently blocked in 1% bovine serum albumin (BSA; Sigma-
Aldrich) in phosphate buffered Saline (PBS) at 4 °C. The 
primary antibody was incubated overnight at 4 °C in 1% 
BSA supplemented with 0.1% Triton X-100 (Carl Roth) for 
cell permeabilization. Secondary antibody was incubated 
for 1 h at RT. Afterwards, Hoechst33342 was incubated for 
10 min at RT before glass cover slips were mounted with 
Fluoromount-G (Thermo Fisher Scientific) on microscope 
slides. Image recording was performed using the LSM 710 
confocal microscopy system. Antibody information is given 
in suppl. Table 3.
RNA extraction
Human myocardium samples were homogenized using 5 mg/
sample in 500 µl of qiazol (Qiagen). Samples were homog-
enized for 30 s using MICCRA D1 dispersing instrument 
at level F (35,000 min−1). Total RNA was extracted using 
miRNeasy blood and tissue kit (Qiagen) following manufac-
turers protocol. Human iPSC-CM pellets were snap frozen 
in liquid nitrogen. For total RNA isolation of cells and mice 
left ventricle, the SV Total RNA Isolation System (Promega) 
or the RNeasy Fibrous Tissue mini Kit (Qiagen) was used.
Protein extraction and proteome analysis
iPSC-CM were washed and transferred with 1 ml 1 × PBS 
into an Eppendorf tube. Cells were centrifuged at 
13,000 rpm for 1 min and resuspended in 50 µl RIPA buffer 
(Thermo Fisher Scientific). After incubation for 10 min, 
cells were centrifuged at 4 °C for 5 min at 5000 rpm and 
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the supernatant was used for analysis. Protein concentration 
was determined using the BCA Assay as described in the 
manufacturer’s instructions (Thermo Fisher Scientific). The 
Generation, quantification and analysis of proteome data is 
detailed in the supplementary methods.
Quantitative real‑time PCR
200 ng of isolated RNA were used for first-strand cDNA 
synthesis (RT2 First strand Kit; Qiagen) according to the 
manufacturer`s instructions. Quantitative real-time PCR 
was performed with RT2 SYBR Green qPCR Mastermix 
(Qiagen) and the CFX96 Real-Time System Thermal Cycler 
(BioRad). The results were analyzed with the ddCT method 
in Excel and normalized to H18S and GAPDH, respec-
tively. T test statistics were performed with GraphPad Prism 
7. Primer information qPCR analyses are listed in suppl. 
Table 4.
mRNA sequencing
mRNA-seq was performed at the Transcriptome and 
Genome Analysis Laboratory (TAL) core facility in Goe-
ttingen. Library preparation was conducted according to 
the instructions of the TruSeq RNA Sample Preparation v2 
Kit from Illumina (Cat. No. RS-122-2002) using 1 µg total 
RNA as starting material. For accurate quantitation of cDNA 
libraries, fluorometric-based QuantiFluor™ dsDNA System 
from Promega (Mannheim, Germany) was used. The size of 
final cDNA libraries was determined using the DNA 1000 
chip (280 bp) on the Bioanalyzer 2100 (Agilent). cDNA 
libraries were amplified and sequenced (SR; 1 × 50 bp; ca. 
40 Mio reads per sample) using the cBot and HiSeq2000 
(Illumina). Sequence images were transformed to bcl files 
with the software BaseCaller (Illumina), and then demulti-
plexed to fastq files with CASAVA v1.8.2. Quality checking 
was done via fastqc. Sequences were aligned to the genome 
reference sequence of Homo sapiens (GRCh38/hg38) or 
Mus musculus (GRCm38/mm10), respectively. The align-
ment was performed using the STAR alignment software 
(version 2.3.0e) 1 allowing for two mismatches within 50 
bases. Subsequently, conversion of resulting SAM files to 
sorted BAM files, filtering of unique hits and counting were 
conducted with SAMtools (version 0.1.19) 2 and HTSeq 
(version 0.6.1p1) 3. Data were preprocessed and analyzed 
in the R/Bioconductor environment (www.bioco nduct or.org) 
using the DESeq2 package (version 1.8) 4. Specifically, the 
data were normalized and tested for differentially expressed 
genes based on a generalized linear model likelihood ratio 
test assuming negative binomial data distribution. Candi-
date genes were filtered to a minimum of  log2FC > 1/− 1 
and a false discovery rate–corrected p value < 0.05. Gene 
annotation was performed using Homo sapiens entries from 
Ensembl (www.ensem bl.org) via the biomaRt package (ver-
sion 2.18.0) 5.
GO and pathway enrichment
Pathway analysis was conducted using significantly regu-
lated genes (cut off  log2FC > 1/− 1; adjusted p value < 0.05 
and cut off  log2FC > 0.5/− 0.5; adjusted p value < 0.05 in 
case of iPSC-CM) of the transcriptomes using Cytoscape 
and ClueGO [6, 41] and KEGG mapper—search and color 
pathway.
Statistics
CaT analysis and animal data were analyzed and are pre-
sented using standard deviation (± SD). All other data were 
analyzed and are presented as mean standard error of the 
mean (± SEM) if not indicated otherwise. All data were sta-
tistically analyzed using Graph pad prism 7 or excel. Differ-
ences by unpaired student’s t test were considered signifi-
cant when p value ≤ 0.05 (or FDR-corrected p value ≤ 0.05 
for RNA-seq results, respectively). Not significant: (n.s.) 
p value > 0.05; p value ≤ 0.05 = *; p value ≤ 0.01 = **; p 
value ≤ 0.001 = ***; p value ≤ 0.0001 = ****.
Study approval
The investigation conforms to the principles outlined in the 
Declaration of Helsinki. The use of patient biopsies was 
approved by the institutional ethics committee (approval 
number: 21/2/11). All patients provided written informed 
consent for the use of cardiac tissue samples. The use of 
hiPSC was approved by the institutional ethics commit-
tee (approval number: 10/9/15) and carried out in accord-
ance with the approved guidelines. All mouse experiments 
(approval number: 13/1291) conform to the Guide for the 
Care and Use of Laboratory Animals (NIH publication No. 
85–23, revised 1996) and were performed in accordance 
with the ethical standards laid down in the Declaration of 
Helsinki 1964.
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